Home › Funds › ADAR1 Capital Management, LLC › AVLN
ADAR1 Capital Management, LLC position in AVLN
AVALYN PHARMACEUTICALS INC · Health Care
ADAR1 Capital Management, LLC reported holding 397,719 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.3M, representing 0.62% of its reported portfolio and ranking #44 among its reported holdings. ADAR1 Capital Management, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's AVLN position evolved
ADAR1 Capital Management, LLC first disclosed a stake in AVLN in Q2 2026 at 146,447 shares (US$4.8M). The position peaked in Q3 2026 at 397,719 shares, worth US$11.3M. Across 2 filings, ADAR1 Capital Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 397,719 shares valued at US$11.3M — an increase of 251,272 shares quarter over quarter.. Notable position changes include a 172% increase in Q3 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 146.45K | $4.82M | New |
| Q3 2026 | 397.72K | $11.33M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVLN and 13F data
AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 118 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- Novo Holdings A/S 3.88M sh · $127.84M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $108.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $88.07M · Q2 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $82.40M · Q2 2026
- NVP Associates, LLC 2.27M sh · $64.63M · Q3 2026
- Catalio Capital Management, LP 1.68M sh · $55.17M · Q2 2026
- Bellevue Group AG 1.35M sh · $44.44M · Q2 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- BRAIDWELL LP 801.39K sh · $26.38M · Q2 2026
- TPG GP A, LLC 773.07K sh · $25.45M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 866.79K sh · $24.69M · Q3 2026
- Rock Springs Capital Management LP 662.92K sh · $18.89M · Q3 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held AVLN?
ADAR1 Capital Management, LLC has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is ADAR1 Capital Management, LLC's current position in AVLN?
As of Q3 2026, ADAR1 Capital Management, LLC holds 397.72K shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $11.33M, representing 0.62% of its reported portfolio and ranking #44.
Has ADAR1 Capital Management, LLC been buying or selling AVLN?
In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in AVLN. The position peaked in Q3 2026 at 397.72K shares.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 118 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.